Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRenalytix Plc Regulatory News (RENX)

Share Price Information for Renalytix Plc (RENX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 26.50
Bid: 26.00
Ask: 27.00
Change: 0.00 (0.00%)
Spread: 1.00 (3.846%)
Open: 26.50
High: 26.50
Low: 26.50
Prev. Close: 26.50
RENX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Renalytix Plc

13 Mar 2024 15:22

Pentwater Capital Management LP - Form 8.3 - Renalytix Plc

Pentwater Capital Management LP - Form 8.3 - Renalytix Plc

PR Newswire

LONDON, United Kingdom, March 13

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:Pentwater Capital Management LP
(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereeRenalytix plc
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure12/03/2024
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state “N/A”No

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:
InterestsShort positions
Number%Number%
(1) Relevant securities owned and/or controlled:4,954,450.004.136%
(2) Cash-settled derivatives:1,049,991.000.8756%
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:6,004,441.005.0072%.

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant securityPurchase/saleNumber of securitiesPrice per unit
EquityPurchase2,589,441.000.20 (GBP)

(b) Cash-settled derivative transactions

Class of relevant securityProduct descriptione.g. CFDNature of dealinge.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitTypee.g. American, European etc.Expiry dateOption money paid/ received per unit

(ii) Exercise

Class of relevant securityProduct descriptione.g. call optionExercising/ exercised againstNumber of securitiesExercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant securityNature of dealinge.g. subscription, conversionDetailsPrice per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”
None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:(i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:If there are no such agreements, arrangements or understandings, state “none”
None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?NO
Date of disclosure:13/03/2024
Contact name:Hooman Tavakolian
Telephone number:+1 312 914 4301

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.



Date   Source Headline
4th Jun 20197:00 amRNSKidneyIntelX commercial scale production milestone
28th May 20197:00 amRNSCLIA Certificate Number issued for Renalytix Lab
21st May 20197:00 amRNSExpansion of FractalDx core investigator group
7th May 20197:00 amRNSUniversity Medical Center Groningen collaboration
2nd May 20192:05 pmRNSSecond Price Monitoring Extn
2nd May 20192:00 pmRNSPrice Monitoring Extension
2nd May 20197:00 amRNSFDA grants Breakthrough Device designation
26th Apr 20196:20 pmRNSAcquisition of further interest in Renalytix AI
26th Apr 20195:42 pmRNSDirector/PDMR Shareholding
2nd Apr 201912:55 pmRNSHolding(s) in Company
1st Apr 20197:00 amRNSPublication of confirmation study results
25th Mar 20197:00 amRNSHalf-year Report
22nd Mar 20197:00 amRNSRenalytixAI Forms Core Investigator Group
12th Mar 20197:00 amRNSInvestor briefing
14th Feb 20197:00 amRNSAppointment of Nomad and Joint Broker
13th Feb 20197:00 amRNSJoint venture partnership agreement with AKESOgen
6th Feb 20197:00 amRNSRenalytixAI Expands Leadership Team
23rd Jan 20197:00 amRNSInitiates Clinical Validation Study
21st Jan 20197:00 amRNSClarification re. lock-up restrictions
2nd Jan 20197:00 amRNSExercise of Option for Exclusive License
20th Dec 20185:20 pmRNSDirector/PDMR Shareholding
20th Dec 20187:01 amRNSPlanned appointment of joint broker & of NOMAD
19th Dec 20186:28 pmRNSDirector Dealing
17th Dec 20181:30 pmRNSHolding(s) in Company
9th Nov 201810:30 amRNSHolding(s) in Company
8th Nov 20184:50 pmRNSHolding(s) in Company
8th Nov 20187:00 amRNSDirector/PDMR Shareholding
6th Nov 20187:00 amRNSRENX Admission to AIM and First Day of Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.